Back

FORTIFY: a phase 2b randomised trial evaluating the effect of orticumab on coronary inflammation (FAI-Score) in post myocardial infarction patients selects for patients with high residual FAI-Score

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Mechanisms of microvascular injury: from neutrophils to no-reflow Inflammation ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Todd Villines

University of Virginia, Charlottesville (United States of America)

5 More presentations in this session

Presentation thumbnail
Inclisiran alleviates myocardial ischemia/reperfusion injury by blocking the HIF-1a/Myo1d-mediated M1 differentiation of macrophages
Doctor L. Guo (Dalian, CN)
Abstract Slides Video
Presentation thumbnail
Gliflozin therapy attenuates persistent systemic inflammation and monocyte metabolic dysfunction post-ACS: a comparative study across the CAD spectrum
Doctor A. Mroueh (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Sex-dependent molecular signatures of reticulated platelets
Doctor S. Kuehne (Augsburg, DE)
Abstract Slides Video
Presentation thumbnail
Neutrophil abundance determines microvascular obstruction in endotoxemia
Mr T. Artner (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Histologic characteristics potentially associated with coronary vasospasm in myocardial infarction cases without apparent epicardial coronary culprit stenosis.
Professor T. Matsuyama (Tokyo, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Mechanisms of microvascular injury: from neutrophils to no-reflow

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
High prevalence of local coronary arterial inflammation in clinically stable subjects after myocardial infarction: findings from the FORTIFY trial screenees
28 August 2026
thumbnail
Congress Session
HOT LINE 5
30 August 2025
thumbnail
Congress Presentation
Depicting inflammation: novel computed tomography approaches in coronary artery disease
31 August 2025
thumbnail
Congress Presentation
TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources